Outcome of adult patients with AML aged <60 years with respect to SDI-group assignment
| End point . | Patients with low SDI, n = 269 . | Patients with high SDI, n = 800 . | P value∗ . | OR/HR (95% CI) . |
|---|---|---|---|---|
| Early death, n (%)†,‡ | 11 (3) | 41 (5) | .52 | 0.73 (0.37-1.43) |
| CR, n (%)‡ | 235 (73) | 681 (75) | .46 | 1.11 (0.84-1.48) |
| Relapse rate, n (%) | 97 (53) | 321 (56) | .49 | 1.13 (0.81-1.57) |
| Patients who died, n (%) | 149 (55) | 522 (65) | .004 | 1.51 (1.14-2.00) |
| DFS | .02 | 1.58 (1.23-2.03) | ||
| Median, y | 2.8 | 1.5 | ||
| Rate at 5 y (95% CI) | 45 (37-52) | 37 (33-41) | ||
| OS | .005 | 1.31 (1.05-1.62) | ||
| Median, y | 3.0 | 1.9 | ||
| Rate at 5 y (95% CI) | 46 (40-52) | 37 (34-41) |
| End point . | Patients with low SDI, n = 269 . | Patients with high SDI, n = 800 . | P value∗ . | OR/HR (95% CI) . |
|---|---|---|---|---|
| Early death, n (%)†,‡ | 11 (3) | 41 (5) | .52 | 0.73 (0.37-1.43) |
| CR, n (%)‡ | 235 (73) | 681 (75) | .46 | 1.11 (0.84-1.48) |
| Relapse rate, n (%) | 97 (53) | 321 (56) | .49 | 1.13 (0.81-1.57) |
| Patients who died, n (%) | 149 (55) | 522 (65) | .004 | 1.51 (1.14-2.00) |
| DFS | .02 | 1.58 (1.23-2.03) | ||
| Median, y | 2.8 | 1.5 | ||
| Rate at 5 y (95% CI) | 45 (37-52) | 37 (33-41) | ||
| OS | .005 | 1.31 (1.05-1.62) | ||
| Median, y | 3.0 | 1.9 | ||
| Rate at 5 y (95% CI) | 46 (40-52) | 37 (34-41) |
OR, odds ratio.
P values for categorical variables are from Fisher exact test; P values for the time-to-event variables are from the log-rank test.
Early death is defined as death within 30 days after start of induction therapy, regardless of cause.
For early death and complete remission analyses the denominator included patients who received an allogeneic hematopoietic stem cell transplantation in first CR (patients with low SDI, n = 323; patients with high SDI, n = 910). All other outcome analyses excluded patients receiving an allogeneic hematopoietic stem cell transplantation in first CR.